FDA discusses measures to avoid failures with new industry fees plan
This article was originally published in Scrip
Executive Summary
The US FDA is pressing on with efforts to gather input on how its next prescription drug user fee programme should be framed and consider how performance failures associated with its current user fee programme, PDUFA IV, can be avoided.